ASCO Annual Meeting: Prostate Cancer | Conference

Almost all patients with nonmetastatic castration-resistant prostate cancer treated on the phase 3 ARAMIS trial were able to receive the full planned dose of darolutamide for their disease.

Disparities regarding comprehensive genomic profiling came to light during a presentation at the 2021 ASCO Annual Meeting.

A 40% reduction in the risk of death was observed when 177Lu-PSMA-617A was added to standard of care therapy in patients with PSMA-positive metastatic castration-resistant prostate cancer.